Preclinical Evaluation of the PI3K/Akt/mTOR Pathway in Animal Models of Multiple Sclerosis
Author
McCubrey, James A.
Date
2018-01-03
Citation:
APA:
McCubrey, James A.. (January 2018).
Preclinical Evaluation of the PI3K/Akt/mTOR Pathway in Animal Models of Multiple Sclerosis.
Oncotarget,
(9:9), p.8263-8277. Retrieved from
http://hdl.handle.net/10342/9647
MLA:
McCubrey, James A..
"Preclinical Evaluation of the PI3K/Akt/mTOR Pathway in Animal Models of Multiple Sclerosis". Oncotarget.
9:9. (8263-8277.),
January 2018.
May 24, 2022.
http://hdl.handle.net/10342/9647.
Chicago:
McCubrey, James A.,
"Preclinical Evaluation of the PI3K/Akt/mTOR Pathway in Animal Models of Multiple Sclerosis," Oncotarget 9, no.
9 (January 2018),
http://hdl.handle.net/10342/9647 (accessed
May 24, 2022).
AMA:
McCubrey, James A..
Preclinical Evaluation of the PI3K/Akt/mTOR Pathway in Animal Models of Multiple Sclerosis. Oncotarget.
January 2018;
9(9)
8263-8277. http://hdl.handle.net/10342/9647. Accessed
May 24, 2022.
Collections